LeMaitre Vascular (LMAT) Rating Increased to Sell at BidaskClub

BidaskClub upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong sell rating to a sell rating in a report issued on Tuesday.

A number of other research analysts have also recently issued reports on the company. Benchmark cut LeMaitre Vascular from a buy rating to a hold rating in a report on Friday, October 27th. Stifel Nicolaus reaffirmed a buy rating on shares of LeMaitre Vascular in a report on Sunday, October 29th. Zacks Investment Research cut LeMaitre Vascular from a buy rating to a hold rating in a report on Wednesday, November 1st. Canaccord Genuity cut their price target on LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a report on Friday, October 27th. Finally, First Analysis cut LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 price target for the company. in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $32.20.

LeMaitre Vascular (LMAT) traded up $0.10 during trading on Tuesday, hitting $32.84. The company had a trading volume of 70,911 shares, compared to its average volume of 124,600. LeMaitre Vascular has a fifty-two week low of $19.82 and a fifty-two week high of $39.88. The company has a market capitalization of $628.81, a PE ratio of 42.65, a price-to-earnings-growth ratio of 2.51 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The business had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. During the same period in the previous year, the business posted $0.17 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. analysts forecast that LeMaitre Vascular will post 0.84 EPS for the current fiscal year.

In related news, insider David B. Roberts sold 4,123 shares of LeMaitre Vascular stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $32.14, for a total value of $132,513.22. Following the completion of the sale, the insider now directly owns 24,482 shares in the company, valued at $786,851.48. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 23.70% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its position in LeMaitre Vascular by 11,612.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 3,716 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $137,000. Victory Capital Management Inc. grew its position in shares of LeMaitre Vascular by 181.2% during the 3rd quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after buying an additional 2,667 shares during the period. Royce & Associates LP acquired a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $156,000. Finally, Royal Bank of Canada grew its position in shares of LeMaitre Vascular by 856.5% during the 2nd quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 4,505 shares during the period. Hedge funds and other institutional investors own 69.24% of the company’s stock.

TRADEMARK VIOLATION WARNING: “LeMaitre Vascular (LMAT) Rating Increased to Sell at BidaskClub” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/17/lemaitre-vascular-lmat-rating-increased-to-sell-at-bidaskclub.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit